XML 36 R25.htm IDEA: XBRL DOCUMENT v3.25.1
Collaborative Arrangements (Tables)
 3 Months Ended
Mar. 31, 2025
Collaborative Arrangements [Abstract]  
Collaboration Arrangements
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20252024
Alliance revenue - Lynparza$312 $292 
Alliance revenue - Koselugo44 38 
Total alliance revenue$356 $330 
Cost of sales (1)
83 82 
Selling, general and administrative32 39 
Research and development12 20 
($ in millions)March 31, 2025December 31, 2024
Receivables from AstraZeneca included in Other current assets
$358 $424 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
15 713 
(1)    Represents amortization of capitalized milestone payments.
(2)    Balance at December 31, 2024 includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20252024
Alliance revenue - Lenvima$258 $255 
Cost of sales (1)
60 60 
Selling, general and administrative31 39 
Research and development5 8 
($ in millions)March 31, 2025December 31, 2024
Receivables from Eisai included in Other current assets
$263 $257 
(1)    Represents amortization of capitalized milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20252024
Alliance revenue - Adempas/Verquvo$106 $98 
Net sales of Adempas recorded by Merck68 70 
Net sales of Verquvo recorded by Merck9 5 
Total sales$183 $173 
Cost of sales (1)
58 62 
Selling, general and administrative29 33 
Research and development24 28 
($ in millions)March 31, 2025December 31, 2024
Receivables from Bayer included in Other current assets
$160 $160 
Payables to Bayer included in Accrued and other current liabilities
83 82 
(1)    Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20252024
Net sales of Lagevrio recorded by Merck
$102 $350 
Cost of sales (1)
53 191 
Selling, general and administrative
13 16 
Research and development
8 (5)
($ in millions)March 31, 2025December 31, 2024
Payables to Ridgeback included in Accrued and other current liabilities (2)
$43 $68 
(1)    Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.
(2)    Includes accrued royalties.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20252024
Selling, general and administrative $9 $3 
Research and development
128 69 
($ in millions)March 31, 2025December 31, 2024
Receivables from Daiichi Sankyo included in Other current assets
$13 $8 
Payables to Daiichi Sankyo included in Accrued and other current liabilities (1)
803 817 
(1) Includes accrued continuation payment.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20252024
Selling, general and administrative $6 $2 
Research and development
86 69 
($ in millions)March 31, 2025December 31, 2024
Payables to Moderna included in Accrued and other current liabilities
$37 $57